Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides

Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), Xue‐hai Liang(Arisan Therapeutics (United States)), Susan Murray(Ionis Pharmaceuticals (United States)), Audrey Low(Ionis Pharmaceuticals (United States)), Michael T. Migawa(Ionis Pharmaceuticals (United States)), Andrés Berdeja(Ionis Pharmaceuticals (United States)), Stanley T. Crooke(Stanley Foundation), Wen Shen(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States)), Guillermo Vasquez(Ionis Pharmaceuticals (United States)), Cheryl Li De Hoyos(Ionis Pharmaceuticals (United States))
Nucleic Acids Research
January 14, 2020
10.1093/nar/gkaa031
Cited by 98

Related Papers

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
|The Lancet|2010|905
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary<i>N</i>-acetyl galactosamine improves potency 10-fold in mice
|Nucleic Acids Research|2014|594
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
|Nucleic Acids Research|2006|461
Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant.
|Molecular and Cellular Biology|1994|354